It sounds like you got profit and cash flow mixed up. Some elements of profit can be changed at the discretion of management all the while staying in compliance with the relevant accounting standards. For example, decisions on depreciation (e.g. estimated useful life or depreciation method) will impact expenses in the P&L while the varying decisions won't change the actual future viability of the company. The fact is that there are minimal opportunities for management to exercise their discretion when presenting cash flows. This is why cash flow reflects a more accurate truth of a company's performance than a P&L. To suggest that profit is the most important measure of firms success because cash is easily manipulated is simply wrong.
If however you believe you are right that is more than ok by me. Varying interpretations of financial statements is what allows informed investors to profit from undervalued securities.
IMO
- Forums
- ASX - By Stock
- LYC
- End of Financial Year
LYC
lynas rare earths limited
Add to My Watchlist
0.84%
!
$8.27

End of Financial Year, page-32
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$8.27 |
Change
-0.070(0.84%) |
Mkt cap ! $7.736B |
Open | High | Low | Value | Volume |
$8.30 | $8.35 | $8.14 | $30.78M | 3.743M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 184 | $8.27 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$8.28 | 38197 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 184 | 8.270 |
1 | 3175 | 8.220 |
2 | 2000 | 8.200 |
4 | 6790 | 8.190 |
2 | 5150 | 8.180 |
Price($) | Vol. | No. |
---|---|---|
8.280 | 38197 | 5 |
8.290 | 13003 | 1 |
8.300 | 16408 | 4 |
8.320 | 7490 | 3 |
8.340 | 10002 | 2 |
Last trade - 16.15pm 04/07/2025 (20 minute delay) ? |
Featured News
LYC (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online